0001104659-21-141457.txt : 20211118 0001104659-21-141457.hdr.sgml : 20211118 20211118202433 ACCESSION NUMBER: 0001104659-21-141457 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211116 FILED AS OF DATE: 20211118 DATE AS OF CHANGE: 20211118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malin Life Sciences Holdings Ltd CENTRAL INDEX KEY: 0001685138 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 211426131 BUSINESS ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO, DUBLIN STATE: L2 ZIP: ---- BUSINESS PHONE: 353 1 901 5701 MAIL ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO, DUBLIN STATE: L2 ZIP: ---- ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 tm2133357-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-11-16 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001685138 Malin Life Sciences Holdings Ltd THE LENNOX BUILDING 50 RICHMOND STREET SOUTH DUBLIN L2 D02 FK02 IRELAND 0 0 1 1 Common director with Issuer COMMON STOCK 2021-11-16 4 P 0 27680 7.167 A 9215805 D COMMON STOCK 2021-11-17 4 P 0 280384 7.2109 A 9496189 D COMMON STOCK 2021-11-18 4 P 0 71312 7.1753 A 9567501 D The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.06 to $7.25 on 11/16/2021; $6.97 to $7.37 on 11/17/2021; and $6.84 to $7.29 on 11/18/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Pat Jennings, Chief Financial Officer 2021-11-18